伊伐布雷定的临床研究进展

Clinical Research Progress of Ivabradine

伊伐布雷定是高度特异性超极化激活的环核苷酸门控通道(If通道)阻滞剂,以剂量依赖性方式抑制If电流降低窦房结节律,由此减慢心率,而对心内传导、心肌收缩力、左室收缩功能或心室复极化无影响.目前许多临床研究表明,伊伐布雷定对冠状动脉粥样硬化性心脏病(冠心病)、心力衰竭患者的临床症状以及预后有明确的改善作用,对快速型窦性心律失常疗效确切.现对伊伐布雷定在冠心病的诊断及治疗、心力衰竭和不适当性窦性心动过速中的应用进行综述.

Ivabradine is a high specificity inhibitor of hyperpolarization activated cyclic nucleotide-gated channels （If channel）, which can inhibit If current in a dose-dependent manner, and reduce heart rate, but it does not affect the myocardial contractility, conduction, left ventricular systolic function or ventricular repolarization. At present, many clinical studies have shown that ivabradine can obviously improve the clinical symptoms and prognosis for the patients with coronary heart disease, heart failure, and that it has a definite curative effect on inappropriate sinus tachycardia. This article summarizes the application of ivabradine in treatment or diagnosis of coronary heart disease, heart failure and inappropriate sinus tachycardia.